Skip to main content
SGLT2 inhibitors tied to increased amputation risk in diabetes

A study in The BMJ showed that diabetes patients who took SGLT2 inhibitors, such as canagliflozin, dapagliflozin and empagliflozin, were at a twofold higher risk of lower limb amputation and diabetic ketoacidosis, compared with users of GLP-1 receptor agonists. Researchers analyzed data on 34,426 diabetes patients from Sweden and Denmark and noted that, based on their findings, patients at high amputation risk "might be monitored more closely if SGLT2 inhibitors are used, and the risk of this adverse event may be considered when deciding on which drugs to use," said lead researcher Dr. Peter Ueda.

Full Story: